Get the Stockscreener App
79.86
1.66%
-1.35
Bio Rad Laboratories Inc stock is traded at $79.86, with a volume of 3.09M.
It is down -1.66% in the last 24 hours and up +0.00% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$81.21
Open:
$80.14
24h Volume:
3.09M
Relative Volume:
4.39
Market Cap:
$15.61B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-21.32
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
-5.47%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$78.60
$80.56
1-Week Range:
$78.60
$89.49
52-Week Range:
$78.60
$89.49
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
79.86 | 16.39B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
111.25 | 191.92B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
339.21 | 133.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.27 | 116.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.83 | 74.52B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.60 | 53.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BBIO) Latest News
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. - The Motley Fool
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories (BIO) Issues Flat Revenue Guidance, Is It Too Far Above Fair Value? - Sahm
Bio-Rad (BIO) Q2 2026 Earnings Call Transcript - aol.com
Bio-Rad Laboratories (NYSE:BIO) Hits New 52-Week HighHere's What Happened - MarketBeat
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock - Yahoo Finance
Bio-Rad Laboratories (BIO) Stock Analysis: Exploring a Potentially Overvalued Healthcare Giant - DirectorsTalk Interviews
Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus - Yahoo Finance
Technical Reactions to BIO Trends in Macro Strategies - Stock Traders Daily
Assenagon Asset Management S.A. Acquires 85,393 Shares of Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at 352.86 USD - Investing.com
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
US$329That's What Analysts Think Bio-Rad Laboratories, Inc. (NYSE:BIO) Is Worth After These Results - 富途牛牛
Bio-Rad's FCPA Review Gets Picked Over at Trial - Law.com
Bio-Rad Laboratories, Inc. $BIO Shares Bought by California State Teachers Retirement System - marketbeat.com
Bio Rad Laboratories (BIO) Stock Jumps As ddPCR Progress Meets Flat Demand - Sahm
BIO-RAD LABORATORIES, INC. : WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310 - webull.com
BIO Maintained by Citigroup -- Price Target Raised to $330 - GuruFocus
Is Bio-Rad Laboratories Inc (BIO) Overvalued After 4.5% Rally? G - GuruFocus
Citigroup Increases Bio-Rad Laboratories (NYSE:BIO) Price Target to $330.00 - MarketBeat
BIO Maintains Rating by Wells Fargo -- Price Target Raised to $3 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Bio-Rad Laboratories (NYSE:BIO) Stock - marketbeat.com
Bio-Rad Laboratories (NYSE:BIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Sets New 52-Week High on Earnings Beat - marketbeat.com
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
BIO SWOT Analysis: Financial Resilience Amidst Market Challenges Revealed in 10-Q Filing - GuruFocus
AUG 04 (REUTERS)BIO-RAD Q2 EPS USD 13.85. - Moomoo
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO - marketbeat.com
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ... By GuruFocus - Investing.com Canada
BIO Looks 4.8% Overvalued on GF Value™ Amid Restructuring Plans - GuruFocus
Bio-Rad Laboratories Q2 Earnings Call Highlights - MarketBeat
Bio-Rad: Q2 Earnings Snapshot - Barchart.com
Is Bio-Rad Laboratories Inc (BIO) Overvalued After Q2 Earnings B - GuruFocus
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates - finance.yahoo.com
Bio-Rad Laboratories, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Bio-Rad tops Q2 2026 estimates, shares fall after hours - Investing.com
BIO Looks 4.8% Overvalued on GF Value™ as Growth Momentum Shines - GuruFocus
BIO Looks 4.8% Overvalued on GF Value™ as Market Weighs 2026 Gui - GuruFocus
Bio-Rad Laboratories Q2 Adjusted Earnings Rise, Revenue Falls - marketscreener.com
Q2 2026 Bio Rad Laboratories Inc Earnings Call Transcript - GuruFocus
Bio-Rad Laboratories (BIO) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.87 EPS - MarketBeat
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Reports Q2 Revenue $651.0M, vs. FactSet Est of $624.0M - marketscreener.com
Earnings Flash (BIO) Bio-Rad Laboratories, Inc. Posts Q2 Adjusted EPS $2.62 per Share, vs. FactSet Est of $1.75 - marketscreener.com
BIO-RAD LABORATORIES, INC. 2Q 2026: Revenue $651M, EPS $13.85— 10-Q Summary - TradingView
Bio-Rad Laboratories (NYSE: BIO) Q2 profit offset by H1 fair-value losses - Stock Titan
Bio Rad Laboratories Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):